{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:14Z","timestamp":1784613914755,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Endometrial carcinoma (EC) of the No Specific Molecular Profile (NSMP) subtype, the largest molecular category, exhibits marked clinical heterogeneity that challenges morphology-based risk assessment. Two complementary biomarker categories have demonstrated independent prognostic value: protein-level markers (L1CAM, oestrogen receptor [ER], and progesterone receptor [PR]) detectable by routine immunohistochemistry and spatially resolved cancer-immune phenotypes (SCIs) that characterize the tumour immune microenvironment. This review synthesises evidence for both, highlighting that they are often considered in isolation. We argue that their systematic integration is essential for a more precise diagnostic framework. We articulate the biological rationale and propose a testable \u201cdual-risk\u201d hypothesis, whereby combined molecular and immune profiling could identify extreme-risk populations. Realising this integrative model requires overcoming standardisation hurdles, but it represents a critical step towards predictive, functionally informed stratification to guide personalised adjuvant therapy decisions, including intensification and de-escalation. We emphasise that this framework remains a testable hypothesis requiring prospective validation before clinical application.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1859445","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:54Z","timestamp":1784612154000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From integrative diagnostics to personalised management: a framework combining molecular and spatial immune profiling in NSMP endometrial carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Lan","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.07.020","article-title":"The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer","volume":"200","author":"Marchetti","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s1470-2045(25)00612-6","article-title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial","volume":"27","author":"van den Heerik","year":"2026","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ajog.2025.09.041","article-title":"Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis","volume":"234","author":"Ferrari","year":"2026","journal-title":"Am J Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215429","article-title":"Integrated biomarker analysis reveals L1CAM as a potential stratification marker for no specific molecular profile high-risk endometrial carcinoma","volume":"14","author":"Ravaggi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.11.005","article-title":"Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer","volume":"192","author":"Kleppe","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"Vrede","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/pgp.0000000000001112","article-title":"Clinicopathological and molecular characterization of high grade endometrial carcinomas of no specific molecular profile (NSMP) stratified by ER status","volume":"45","author":"Timmermans","year":"2026","journal-title":"Int J Gynecol Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-021-06385-0","article-title":"Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis","volume":"306","author":"Travaglino","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/pgp.0000000000000865","article-title":"Clinicopathologic evaluation of CTNNB1 mutations in high-intermediate risk endometrial endometrioid carcinoma","volume":"42","author":"Haag","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/s1470-2045(25)00680-1","article-title":"Is PORTEC-4a the tipping point in endometrial cancer management","volume":"27","author":"Betella","year":"2026","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1442441","article-title":"The role of CTNNB1 in endometrial cancer","volume":"2022","author":"Ledinek","year":"2022","journal-title":"Dis Markers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100624","article-title":"Spatial cancer-immune phenotypes predict shorter recurrence-free survival in the no specific molecular profile molecular subtype of endometrial carcinoma","volume":"38","author":"de Biase","year":"2025","journal-title":"Mod Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-20-0149","article-title":"Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer","volume":"8","author":"Horeweg","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00262-024-03919-8","article-title":"Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification","volume":"74","author":"Hattori","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-2559.2009.03327.x","article-title":"Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition","volume":"55","author":"Stewart","year":"2009","journal-title":"Histopathology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4161\/cam.20832","article-title":"L1CAM: a major driver for tumor cell invasion and motility","volume":"6","author":"Kiefel","year":"2012","journal-title":"Cell Adh Migr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/bio.2013.0091","article-title":"National Cancer Institute Biospecimen Evidence-Based Practices: a novel approach to pre-analytical standardization","volume":"12","author":"Engel","year":"2014","journal-title":"Biopreserv Biobank"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1859445\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:55Z","timestamp":1784612155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1859445\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1859445"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1859445","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1859445"}}